An Open-Label Extension Study for Patients With Dravet Syndrome Who Previously Participated in Studies of STK-001
Latest Information Update: 04 Sep 2024
At a glance
- Drugs Zorevunersen (Primary)
- Indications Dravet syndrome
- Focus Adverse reactions
- Acronyms SWALLOWTAIL
- Sponsors Stoke Therapeutics
- 03 Sep 2024 According to a Stoke Therapeutics media release, data from the study will be presented at the 15th European Epilepsy Congress (EEC) taking place September 7 - 11, in Rome, Italy.
- 07 May 2024 Planned number of patients changed from 69 to 60.
- 25 Mar 2024 Landmark new results data from this trial presented in a Stoke Therapeutics media release.